Pharmacogenetics, the study of genetically determined variations in drug response, has its origins in discoveries made in the 1950s. In 1957, Motulsky (1) pointed out that certain adverse drug reactions could be caused by genetically determined variations in enzyme activity. It was recognized that variants of glucose-6-phosphate dehydrogenase caused primaquine-induced hemolysis (2) and that pseudocholinesterase variants caused sensitivity to suxamethonium (3) . At the same time, genetic variation in the capacity to perform acetylation reactions was found to be related to adverse effects of isoniazid (4) . In 1959, Vogel (5) first proposed the term "pharmacogenetics", and in 1962, Kalow (6) wrote the first monograph on the subject. Numerous additional examples of pharmacogenetic traits have been described since.
The field of pharmacogenetics was further stimulated in the 1970s when Vesell and his colleagues (7) demonstrated that identical twins were more similar than were fraternal twins in regard to the plasma half-lives of numerous drugs. The implication was that multiple genes may determine individual drug biotransformation (multigenic inheritance). More recently, genetic polymorphisms of drugmetabolizing enzymes with monogenic inheritance such as debrisoquine polymorphism, mephenytoin polymorphism, and acetylation polymorphism have received much interest because they affect the metabolism of numerous clinically useful drugs and concern a sizeable proportion of patients (8) (10-20%6) . By contrast, inefficient or slow metabolism of the anticonvulsant mephenytoin and some other drugs, another recessively inherited deficiency of a drug-metabolizing enzyme (8) , is infrequent in Caucasians (3-5%) and more common (15-20%) in Asians. The importance of these population differences in the incidence of enzyme variants has only recently been the subject of epidemiological and clinical investigations (10) .
Like most areas of biomedical science, pharmacogenetics has been profoundly transformed by molecular biology. Many pharmacogenetic conditions are now being studied at the gene level. Simple PCR-based DNA tests for the debrisoquine and the acetylation polymorphism were developed in my laboratory in 1990 (11) and 1991 (9), respectively. Similarly, the many variants of pseudocholinesterase (12) or of glucose--phosphate dehydrogenase (13) can now be assessed by DNA technology, rather than by the difficult characterization of the enzyme itself.
The best-studied example of a genetic variation in drug response is the debrisoquine polymorphism. Five to 10% of individuals in Caucasian populations are so-called "poor metabolizers" and are homozygous for two recessive loss-offunction alleles of the CYP2D6 gene encoding the microsomal cytochrome P450 monooxygenase CYP2D6 (8, 14) . These poor metabolizers of debrisoquine are inefficient in the metabolism of >30 clinically used drugs, including important antidepressants, neuroleptics, opioids, and cardiovascular drugs. Moreover, a higher frequency of some of the mutant alleles is observed in patients with Parkinson disease, and this suggests a role of this enzyme in the pathogenesis of this neurodegenerative disorder (15, 16) .
In the last 5 years, >90% of the mutations of the CYP2D6 gene that cause absence of the CYP2D6 protein and result in the debrisoquine poor-metabolizer phenotype have been identified (17) (18) (19) . As for other human enzyme deficiencies, many different mutations can cause a defective enzyme. The most common mutant allele (>70%o of poor-metabolizer alleles) is characterized by a point mutation at a splice-site recognition sequence that leads to a frameshift. Another mutant allele (5%) consists of a 1-bp deletion in the coding sequence, causing a frameshift, and yet another loss of enzyme activity (10-15%) is caused by the deletion of the entire CYP2D6 gene (20) .
The mutations described provide a molecular explanation for the subgroup of poor metabolizers. However, the enormous variation among the individuals of the much larger group of so-called "extensive metabolizers," remained unexplained. These individuals presumably carry one or two normal (or wild-type) alleles of CYP2D6. But extensive (or rapid) metabolizers with a known mutant allele of CYP2D6 (heterozygotes) were on the average only slightly "slower" and not clearly distinguishable from those with two normal CYP2D6 genes (19) . Additional genetic or epigenetic variation was suspected. Environmental factors causing enzyme induction or repression appeared of negligible importance because in the same individual the debrisoquine urinary metabolic ratios are constant over years. Recent studies have shed some light on this problem in that several CYP2D6 alleles that result in only slightly decreased metabolism ofdebrisoquine have been observed (21, 22) . These mutations explain the so-called "intermediate metabolizer" phenotype-i.e., individuals that are on the "slow side" of the extensive metabolizer distribution curve but are not really poor metabolizers.
In this journal, Johansson et al. (23) added another dimension to our understanding of the CYP2D6 locus and to pharmacogenetic variation in general. In two families of extremely rapid metabolizers of debrisoquine, designated by the authors as "ultrarapid metabolizers," they discovered amplification of functional CYP2D6 genes. With studies in two families, they provide convincing genetic evidence that this amplification causes ultrarapid metabolism.
The CYP2D6 gene was amplified 12- fold on one allele in three members of one family, and two gene copies were present on one allele in another family of ultrarapid metabolizers. The duplicated or amplified CYP2D6 is a common variant of the initially described CYP2D6 wild- (30) . Understanding the mechanisms and consequences of amplification in normal cells remains a major challenge for the future.
At this time, the findings of Johansson et al. (23) provide a molecular explanation for extremely rapid drug metabolism in individuals that require much higher than usual doses to reach therapeutic drug concentrations. Gene amplification in the described individuals represents a predictable pharmacogenetic trait complicating drug therapy and a novel source of interindividual variation in drug response.
